News

StemCells has reported that it will soon initiate, along with the University of California, San Francisco (UCSF) Children’s Hospital, a phase I clinical trial to evaluate the therapeutic

Mpex Pharmaceuticals (Mpex) has reported positive data from its phase 2b clinical trial with Aeroquin (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Reportedly, the

United BioSource (UBC) has acquired Cognitive Drug Research (CDR). The CDR System is used in 1000 trials encompassing approximately 50 different disease areas. CDR maintains healthy subject, patient,

Acceleron Pharma (Acceleron) has provided preliminary results from the ACE-031 phase 1 single dose clinical trial, demonstrating that ACE-031 increased lean body mass and muscle volume. The results

CytRx has been granted a key patent by the European Patent Office that covers through 2024 the use of its orally available molecular chaperone amplifier drug candidate –

Generex Biotechnology (Generex) has reported that the FDA has granted approval for its Oral-lyn under the FDA’s Treatment Investigational New Drug (IND) program. Reportedly, the drugs that are

Access Pharmaceuticals has provided an update on its clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor

QuatRx Pharmaceuticals (QuatRx) has reported positive efficacy results from the second of two patient cohorts in the second pivotal phase 3 study of Ophena (ospemifene tablets). Ophena is

Teva Pharmaceutical (Teva) has provided data that demonstrated patients treated for 10 and 15 years with Copaxone had significant reduction in disease severity. The long-term analysis utilised the